Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 28, Issue 6, Pages 1178-1188
Publisher
Springer Science and Business Media LLC
Online
2022-06-05
DOI
10.1038/s41591-022-01851-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
- (2022) Alexander C. J. van Akkooi et al. ANNALS OF SURGICAL ONCOLOGY
- Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
- (2022) Irene L. M. Reijers et al. JAMA Surgery
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
- (2021) E. A. Rozeman et al. NATURE MEDICINE
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma
- (2021) Judith M. Versluis et al. EUROPEAN JOURNAL OF CANCER
- Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
- (2021) R.V. Rawson et al. ANNALS OF ONCOLOGY
- Application of ultrasound-guided placement of markers for locating axillary lymph nodes of breast cancer
- (2021) Xiaohui Ji et al. Gland Surgery
- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
- (2020) Reinhard Dummer et al. LANCET ONCOLOGY
- Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
- (2020) Alexander M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- 1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone
- (2020) C. Robert et al. ANNALS OF ONCOLOGY
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- Long-term safety and efficacy of breast biopsy markers in clinical practice
- (2020) Sharon Smith et al. Expert Review of Medical Devices
- Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma
- (2019) B. Schermers et al. BRITISH JOURNAL OF SURGERY
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
- (2019) Y J L Jansen et al. ANNALS OF ONCOLOGY
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In‐transit Disease
- (2019) J. Weber et al. BRITISH JOURNAL OF DERMATOLOGY
- Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research
- (2019) Johannes M. Giesinger et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- (2018) M T Tetzlaff et al. ANNALS OF ONCOLOGY
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema
- (2017) Caroline A. Gjorup et al. EUROPEAN JOURNAL OF CANCER
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Pointwise confidence intervals for a survival distribution with small samples or heavy censoring
- (2013) Michael P. Fay et al. BIOSTATISTICS
- Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2010) Kim Cocks et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma
- (2009) Mattijs de Vries et al. ANNALS OF SURGICAL ONCOLOGY
- Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection
- (2009) Lutz Kretschmer et al. MELANOMA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started